Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarissa’s Stake in Vivus, Inc. (VVUS) Points to Renewed Interest in the Company

VIVUS, Inc. (NASDAQ:VVUS)Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS, Inc. (NASDAQ:VVUS) . Although it had been widely anticipated by keen-eyed market observers, this event nevertheless highlighted the renewed interest in VIVUS’ long-term prospects.

Like many small biotech firms that focus on developing and marketing experimental or advanced drugs, VIVUS has had a volatile run over the past few years. After several quarters in the doghouse, VIVUS, Inc. (NASDAQ:VVUS) may finally be benefiting from a promising pipeline and could even become an acquisition target at some point in the future.

Moreover, the firm has continued to attract the attention of activist investors. With Sarissa’s chief investment officer looking to snag a spot on VIVUS’ board, some big changes could be on the way. Investors who wish to take advantage of this potentially profitable opportunity may wish to take a closer look at the company’s fundamentals.

Stacking VIVUS against the competition

As a small-scale biotechnology company with big plans, VIVUS, Inc. (NASDAQ:VVUS) competes against obscure and recognizable firms alike. Despite its relatively paltry $1.5 billion market capitalization, VIVUS enjoys such rarefied company as Eli Lilly & Co. (NYSE:LLY) and GlaxoSmithKline plc (NYSE:GSK). This is partially due to the fact that its most promising drugs and compounds are designed to fight common medical conditions like obesity and adult diabetes. Unlike its smaller and riskier peers, VIVUS avoids rare-disease drugs that can be extremely profitable but have limited marketability.

Eli Lilly & Co. (NYSE:LLY) and GlaxoSmithKline plc (NYSE:GSK) have market capitalization of about $59 billion and $128 billion, respectively. Relative to VIVUS, Inc. (NASDAQ:VVUS), they are also extremely profitable. Compared to VIVUS’ operating margin of minus 2850%, Glaxo reported a profit margin of about 16%. Lilly’s margin came in at nearly 20.5%. In some respects, comparing the companies on these metrics is unfair. Despite a promising pipeline, VIVUS is yet to market a blockbuster drug. In 2012, the company lost about $175 million on revenue of just over $6 million. Glaxo earned $14.5 billion on $42.2 billion in revenue, and Eli Lilly & Co. (NYSE:LLY) reported a take of $4.6 billion on revenue of $22.6 billion.

As might be expected, the companies’ balance sheets also vary wildly. VIVUS, Inc. (NASDAQ:VVUS) maintains a cash reserve of about $150 million and reported no debt in the most recent quarter. However, its cash bleed of $180 million may soon pose a problem. By comparison, Eli Lilly & Co. (NYSE:LLY) has about $1 in debt for every $1 in cash on hand. Glaxo has about five times as much debt as cash. Both of these companies have cash flow figures that match or exceed their total cash reserves.

Sarissa Capital Management’s stake

Sarissa accumulated its stake in VIVUS relatively quickly. According to the company’s filing, the acquisition came between late March and late May 2013. Although the stake itself is not particularly large, it is noteworthy because of its association with activist First Manhattan Company. This hedge fund owns about 10% of VIVUS and has actively pursued a shakeup of the company’s board. Its close alliance with Sarissa principal Alex Denner all but guarantees that Sarissa’s shares will vote in lockstep with First Manhattan’s. As such, it can be said that the Sarissa stake boosts First Manhattan’s total stake in the company to about 12%.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.